Dr. Hardy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
22 S. Greene Street
UMGCC; Room 9NE12
Baltimore, MD 21201Phone+1 410-328-1230Fax+1 410-328-1975- Is this information wrong?
Education & Training
National Cancer InstituteFellowship, Stem Cell Transplantation and Immunotherapy, 2003 - 2006
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1999 - 2003
Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001- Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 1999
- Duke University HospitalResidency, Internal Medicine, 1995 - 1998
University of Washington School of MedicineClass of 1995
Certifications & Licensure
WA State Medical License 2010 - 2024
MD State Medical License 2004 - 2024
NC State Medical License 1998 - 2022
DC State Medical License 2013 - 2014
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Start of enrollment: 2010 Dec 10
- Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2011 Mar 30
- MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC Start of enrollment: 2015 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.Kline, K., Luetkens, T., Koka, R., Kallen, M., Chen, W., Ahmad, H., Omili, D., Iraguha, T., Gebru, E., Fan, X., Miller, A., Dishanthan, N., Baker, J., Dietze, K., Hank...> ;Cancer Immunology, Immunotherapy. 2024 Feb 13
- A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products.Djordje Atanackovic, Thierry Iraguha, Destiny Omili, Stephanie V Avila, Xiaoxuan Fan, Mehmet Kocoglu, Etse Gebru, Jillian M Baker, Nishanthini Dishanthan, Kenneth A Di...> ;Cytotherapy. 2024 Apr 1
- 3 citationsImaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response byF-FDG PET/CT Imaging Following CAR-T Therapy.Lutfi, F., Goloubeva, O., Kowatli, A., Gryaznov, A., Kim, D., Dureja, R., Margiotta, P., Matsumoto, L., Bukhari, A., Ahmed, N., Mushtaq, M., Law, J., Lee, S., Kocoglu,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Oct 1
- Join now to see all
Abstracts/Posters
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...Nancy M. Hardy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain BarrierNancy M. Hardy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Hardy: HSCT for the Intensivist: Indications, Interventions, & ComplicationsJanuary 8th, 2017
Professional Memberships
- Member
- Fellow
- Member
- Member
- Society for the ImmunoTherapy of CancerMember
- American Society for Blood and Marrow TransplantationMember
Hospital Affiliations
University of Maryland Medical CenterBaltimore, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
